CNS

#CNS #Gene therapy #Skylark Bio

Skylark Bio expands gene therapy pipeline into CNS

Skylark Bio has revealed it is expanding its pipeline with SKY-AS, a differentiated gene therapy candidate designed to restore UBE3A expression in individuals with Angelman syndrome (AS).   SKY-AS represents the company’s first central nervous system (CNS) development programme and expands Skylark’s portfolio of precision, locally delivered… Read More

#News

Merge road sign
#CNS #Mergers and acquisitions #Supernus Pharmaceuticals

Merger creates CNS biopharma worth $2.2 billion

Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceutical company.  The companies expect the transaction to generate significant value for stockholders of both companies, realising… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #CNS #Collaboration #Drug discovery

Insilico Medicine and CMS announce CNS disease collaboration 

Insilico Medicine, a clinical-stage biotechnology company driven by generative artificial intelligence (AI), and China Medical System Holdings has announced an AI‑empowered drug discovery collaboration.   The collaboration is targeting a mass-market indication in central nervous system (CNS) with an innovative mechanism of action (MoA) identified by PandaOmics. According to the collaboration agreement, the two parties will jointly advance the co-development… Read More

#News

#CNS #Financing #Gene therapy #Latus Bio

Latus Bio announces $97 million series A financing

Gene therapy company Latus Bio has closed a $97 million Series A financing to support its therapeutics pipeline.   The financing includes a $43 million extension led by 8VC, with participation from existing investors DCVC Bio, BioAdvance, Benjamin Franklin Technology Partners, Modi Ventures, Gaingels, and Hatch BioFund. … Read More

#Business & Investment #News

Biochemists working in the lab
#Artificial intelligence (AI) #Autoimmune disease #CNS #Collaboration #Insilico Medicine

Insilico and CMS announce CNS and autoimmune collaboration

Insilico Medicine and China Medical System (CMS) have announced a series of AI‑empowered drug discovery collaborations in the fields of central nervous system and autoimmune diseases.  According to the collaboration agreement, the parties will combine Insilico Medicine’s AI-enabled drug discovery and development capabilities with CMS’s… Read More

#Business & Investment #News

Node structures in the central nervous system
#Alzheimer's #Biotech #CNS #Insilico Medicine #Parkinson's

Insilico and Hygtia Therapeutics partner on CNS disease drug 

Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but… Read More

#Business & Investment #News

B-cells in multiple myeloma
#Cancer immunotherapy #Clinical development #CNS #Essential Pharma #Rare disease

New podcast: From established medicines to rare disease innovation

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Emma Johnson, CEO… Read More

#News

#CNS #Exosomes #Interview #Regenerative Medicine #Spinal cord injury

Regenerate, rewire, recover: Exosome-based therapy regenerates nerves

NurExone Biologics has been named a finalist in Falling Walls Venture 2025, a global platform that showcases the world’s most promising science-based start-ups. With plans to move into clinical trials next year with an exosome therapy for spinal cord injuries, Diana Turner caught up Dr Lior Shaltiel, CEO… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Alzheimer's #CNS #Gene editing #Human disease models #Interview #Neurodegenerative disorders #Neurology #Neuropsychiatric disorders #Neuroscience #Precision medicine #PrecisionLife #Stem cells

Podcast: Unlocking neuroscience drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Innovative uses for biomarkers in drug discovery”, which covers three articles written for DDW Volume 24 – Issue 4, Fall 2023. They are called: “Advances in neuroscience drug discovery”, “Putting human data at the centre of… Read More

#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Last chance: Discover opportunities in ion channel drug discovery

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Discover why ion channels don’t have to be difficult drug discovery targets

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

#ALS #Arbor Biotechnologies #CNS #Financing #Gene therapy

Gene editing company announces $73.9m Series C financing

Arbor Biotechnologies has announced the closing of a $73.9 million Series C financing to support the advancement of its pipeline of novel gene editing therapeutics targeting diseases in the liver and central nervous system (CNS).   The proceeds will support clinical development of the company’s lead therapeutic candidate,… Read More

#Business & Investment #News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Register now: Understand current and future ion channel targets

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets #Webinar

Webinar: Current trends in ion channel drug discovery

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, will provide data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the… Read More

Webinar date:
Supported by Axxam
#News

Ion channel modulators
#CNS #Drug discovery #Ion channel modulators #Therapeutic targets

Ion channel drug discovery – current trends and future opportunities

Ion channels are often regarded as ‘difficult’ drug discovery targets, but this webinar, hosted by DDW and supported by Axxam, provides data and insights showing that this negative perception is inaccurate and that there has been remarkable progress in bringing novel ion channel modulators into the clinic over the last… Read More

Webinar date:
Supported by Axxam
#Webinars

Human brain
#Acquisition #CNS #Excessive Daytime Sleepiness (EDS) #Narcolepsy #Neuraxpharm #Neuroscience #TG Therapeutics

Narcolepsy acquisitions to boost Neuraxpharm’s CNS reach

Pharmaceutical company Neuraxpharm, focused on the treatment of central nervous system (CNS) disorders, has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of Excessive Daytime Sleepiness (EDS) in adults with narcolepsy. Neuraxpharm has acquired these products in most markets outside the US, excluding the… Read More

#Business & Investment #News